{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-001007","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.453575+00:00","generated_at":"2026-05-31T10:42:44.717145+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec","bullets":["Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.","Cash $79.7M as of June 30, 2024; expects runway into Q3 2025.","Jason Tardio (ex-Novartis, Biogen) appointed COO and President effective July 12, 2024.","Simona Skerjanec (ex-Roche Neuroscience head) joined Board of Directors July 22, 2024.","Phase 2 CALLIPER top-line data for vidofludimus calcium in PMS expected April 2025; ENSURE Phase 3 RMS trials on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-001007","json":"https://secwatch.observer/filing/0001193805-24-001007.json","markdown":"https://secwatch.observer/filing/0001193805-24-001007.md","text":"https://secwatch.observer/filing/0001193805-24-001007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/0001193805-24-001007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/e663826_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:42:44.717145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}